🇺🇸 FDA
Pipeline program

Puxitatug Samrotecan

D6900C00003

Phase 3 small_molecule active

Quick answer

Puxitatug Samrotecan for Endometrial Cancer is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Endometrial Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials